share_log

RenovoRx (NASDAQ:RNXT) Stock Price Down 7.6%

Defense World ·  Jan 19, 2023 02:12

RenovoRx, Inc. (NASDAQ:RNXT – Get Rating)'s stock price traded down 7.6% during trading on Wednesday . The stock traded as low as $3.54 and last traded at $3.65. 354,715 shares traded hands during trading, an increase of 346% from the average session volume of 79,574 shares. The stock had previously closed at $3.95.

RenovoRx Stock Performance

The company has a market cap of $33.11 million, a price-to-earnings ratio of -3.72 and a beta of 0.25. The stock's fifty day moving average is $2.23 and its two-hundred day moving average is $2.13.

Get RenovoRx alerts:

RenovoRx (NASDAQ:RNXT – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, equities research analysts expect that RenovoRx, Inc. will post -1.11 EPS for the current year.

Hedge Funds Weigh In On RenovoRx

Large investors have recently bought and sold shares of the stock. Colony Group LLC purchased a new stake in shares of RenovoRx in the third quarter valued at about $32,000. Vanguard Group Inc. bought a new position in shares of RenovoRx during the 1st quarter worth approximately $32,000. Bank of America Corp DE bought a new position in shares of RenovoRx in the first quarter valued at approximately $44,000. Cohen Lawrence B increased its position in shares of RenovoRx by 79.5% during the second quarter. Cohen Lawrence B now owns 97,165 shares of the company's stock valued at $192,000 after acquiring an additional 43,044 shares during the last quarter. Finally, Bank of The West bought a new stake in RenovoRx during the second quarter worth $1,931,000. 13.56% of the stock is currently owned by institutional investors.

RenovoRx Company Profile

(Get Rating)

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.

Featured Stories

  • Get a free copy of the StockNews.com research report on RenovoRx (RNXT)
  • Procter & Gamble Earnings: A Gamble Worth Taking
  • Stocks Slide, Economic Report Paints Gloomy Picture For Economy
  • What does Nu Holdings Stock Have To Do With Warren Buffett?
  • J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
  • Is Intel Stock On The Verge Of Breaking Out?

Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment